MargatoxinAlternative Names: MgTX
Latest Information Update: 26 Jul 2001
At a glance
- Originator Merck & Co
- Class Venoms
- Mechanism of Action Immunosuppressants; Lymphocyte inhibitors; Potassium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Autoimmune disorders; Transplant rejection
Most Recent Events
- 26 Jul 2001 No-Development-Reported for Transplant rejection in USA (Unknown route)
- 26 Jul 2001 No-Development-Reported for Autoimmune disorders in USA (Unknown route)
- 27 May 1997 New profile